1020325-30-7Relevant articles and documents
Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model
Bhuniya, Debnath,Kharul, Rajendra K.,Hajare, Atul,Shaikh, Nadim,Bhosale, Sandeep,Balwe, Sandip,Begum, Fouzia,De, Siddhartha,Athavankar, Sonalee,Joshi, Dhananjay,Madgula, Vamsi,Joshi, Kaushal,Raje, Amol A.,Meru, Ashwinkumar V.,Magdum, Amol,Mookhtiar, Kasim A.,Barbhaiya, Rashmi
supporting information, p. 238 - 243 (2018/12/05)
Conceptual design and modification of urea moiety in chemotype PF-3845/04457845, the bench marking irreversible inhibitor of fatty acid amide hydrolase (FAAH), led to discovery of a novel nicotinamide-based lead 12a having reversible mechanism of action.
AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF
-
Paragraph 0167-0168, (2015/03/16)
The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont
AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF
-
Page/Page column 47, (2013/04/10)
The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont
Discovery of PF-04457845: A highly potent, orally bioavailable, and selective urea FAAH inhibitor
Johnson, Douglas S.,Stiff, Cory,Lazerwith, Scott E.,Kesten, Suzanne R.,Fay, Lorraine K.,Morris, Mark,Beidler, David,Liimatta, Marya B.,Smith, Sarah E.,Dudley, David T.,Sadagopan, Nalini,Bhattachar, Shobha N.,Kesten, Stephen J.,Nomanbhoy, Tyzoon K.,Cravatt, Benjamin F.,Ahn, Kay
scheme or table, p. 91 - 96 (2011/03/23)
Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide. Genetic or pharmacological inactivation of FAAH leads to analgesic and anti-inflammatory phenotypes in rodents without showing the undesirable side effects observed with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for the treatment of inflammatory pain and other nervous system disorders. Herein, we report the discovery and characterization of a highly efficacious and selective FAAH inhibitor PF-04457845 (23). Compound 23 inhibits FAAH by a covalent, irreversible mechanism involving carbamylation of the active-site serine nucleophile of FAAH with high in vitro potency (kinact/Ki and IC50 values of 40300 M-1 s-1 and 7.2 nM, respectively, for human FAAH). Compound 23 has exquisite selectivity for FAAH relative to other members of the serine hydrolase superfamily as demonstrated by competitive activity-based protein profiling. Oral administration of 23 at 0.1 mg/kg results in efficacy comparable to that of naproxen at 10 mg/kg in a rat model of inflammatory pain. Compound 23 is being evaluated in human clinical trials.
4- [3- (ARYLOXY) BENZYLIDENE] -3-METHYL PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS
-
Page/Page column 25, (2009/12/02)
The present invention relates to compounds of Formula (I), wherein Ar is optionally substituted phenyl or heteroaryl and X, Y and Z are independently N or CH; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.
4- [3- (ARYLOXY) BENZYLIDENE] -3-METHYL PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS
-
Page/Page column 25, (2009/12/02)
The present invention relates to compounds of Formula (I), wherein Ar is a 5-membered heteroaryl moiety and X, Y and Z are independently N or CH; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.
BIARYL ETHER UREA COMPOUNDS
-
Page/Page column 17-18, (2008/12/04)
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity
